Purpose: We wanted to compare phenotyping and HFE genotyping for diagnosis of hemochromatosis in 150 family members of 61 probands. Methods: Phenotypes were defined by persistent transferrin saturation elevation, iron overload, or both; genotypes were defined by HFE mutation analysis. Results: Twenty-five family members were C282Y homozygotes; 23 of these (92%) had a hemochromatosis phenotype. Twenty-three family members had HFEgenotype C282Y/H63D; eight of these (35%) had a hemochromatosis phenotype. Six of 102 (6%) family members who inherited other HFE genotypes had a hemochromatosis phenotype. Conclusion: Phenotyping and genotyping are complementary in diagnosing hemochromatosis among family members of probands. Genetics in Medicine, 1999; 1(3):8%93
INTRODUCTION
Hemochromatosis is an autosomal recessive disorder that affects approximately 0.5% of Caucasians of European descent.'s2 Iron absorption in homozygotes is inappropriately high for body iron content, and many subjects have progressive iron deposition that causes injury to the liver, joints, pancreas, heart, and other orgam2 Two hemochromatosis-associated mutations in the HFE gene on chromosome 6p have been identified: cDNA nucleotide 845 G+A (C282Y) and 187 C+G (H63D).3 These mutations do not occur simultaneously on the same chromo~o m e .~-~ To assess HFE genotyping of family members of hernochromatosis probands as a means to identify persons with a hernochromatosis phenotype or to assess their risk for iron overload, we performed a prospective analysis of probands and their family members who volunteered to undergo clinical assessments for phenotypic evidence of hernochromatosis and HFE mutation analysis.
PATIENTS AND MnHODS

Identification of probands and family members
The performance of this study was approved by the Research and Human Use Committees of Brookwood Medical Center and the University of Alabama at Birmingham. We identified consecutive hernochromatosis probands diagnosed during routine medical care delivery from June 1996 to June 1998. After appropriate genetic counseling, probands and family members were offered the opportunity to undergo testing for HFE gene mutations and clinical laboratory assessments as a part of a research protocol. No relatives of probands were diagnosed to have hernochromatosis before their entry into this study. All
persons who participated were Caucasians and were volunteers, but were not otherwise selected. All probands were adults ( 2 18 years of age); all family members (except an 11-year-old boy) were also adults. We tabulated data on all evaluable family members and their corresponding probands.
Diagnosis of hemochromatosis and evaluation of iron overload
Probands
Each proband was diagnosed and evaluated for iron overload as previously de~cribed.~ We used the working diagnostic criterion for hernochromatosis of the American College of Pathologists: elevated fasting transferrin saturation ( r 60% males, r 50% females) on at least two occasions in the absence of other known ~a u s e s .~ Iron overload was defined as evidence of systemic iron overload demonstrated by otherwise unexplained elevated serum ferritin concentration ( r 300 ng/mL in men, 2 200 ng/mL in women), increased hepatic iron content determined using hepatic biopsy specimens, or iron r 4 g mobilized by p h l e b o t~m y .~~ Concentrations of serum ferritin used in this paper to diagnose iron overload are based on current recommendations for initiating phlebotomy treatment for hemochromatosis.' Genetic criteria were not used to establish the diagnosis of hernochromatosis in probands.
Family members
In family members, a hernochromatosis phenotype was defined as the presence of elevated transferrin saturation or iron overload or both (as described above). Blood specimens for analysis of serum iron parameters (serum transferrin saturation, serum ferritin concentration) and HFE genotype were drawn simultaneously in each family member who volunteered to participate in this study. Family members who had abnormal serum iron parameters underwent subsequent clinical evaluations similar to those of pro band^.^-' In all subjects, serum iron parameters, general clinical evaluation, and analysis of the HFE mutant alleles (C282Y and H63D) and wild-type (wt) allele were performed as previously de~cribed.~
Statistical considerations
Our data set consisted of observations of 61 probands and 150 family members. Thirty-five additional probands were diagnosed during the study interval. They had similar clinical phenotypes and HFE genotypes to those of the 61 probands described herein but were not included because they had no family members who volunteered for evaluation. Descriptive data are presented as percentages or means f 1 SD; statistical con~parisons were performed using chi-square analysis.
RESULTS
Relationship of hemochromatosis phenotype and HFE genotype
Probands
Among 61 probands, 42 (68.9%) were men and 19 (31.1%) were women ( Table 1 ). The mean age of the 6 1 probands was 54 t 13 years. Of all probands, 51 (83.6%) had two HFE mutations, 7 ( 1 1.5%) had a single HFE gene mutation, and 3 (4.9%) had no detectable HFE mutation. These frequencies are similar to those previously reported in hemochromatosis probands from our geographic area.? All of our probands had iron overload. Ten ( 16.4%) had hepatic cirrhosis and three (4.9%) had diabetes mellitus attributed to iron overload; each of these probands was homozygous for the C282Y mutation. In aggregate, iron overload was more severe among probands who were C282Y homozygotes than among probands who had other HFE genotype^.^,""
Family members
Among 150 family members, 72 (48.0%) were men and 78 (52.0%) were women; the mean age of the family members was 46 5 15 years. Thirty-four of 150 (22.7%) had a hemochromatosis phenotype and 60 of 150 (40.0°/o) had two HFE mutations (Tables 2 and 3 ). Among 94 first-degree family members (parents, children, siblings), 30 (3 1.9%) had a hemochromatosis phenotype. Among 56 non-first-degree family members, four (7.1 %) had a hemochromatosis phenotype. Altogether, 30 of 34 (88.2%) family members with a hemochromatosis phenotype were first-degree relatives of probands.
Twenty-five family members were homozygous for the C282Y mutation. Each of these was a blood relative of the proband, and 14 of 25 (56.0%) were siblings of probands (Table 2) . A hemochromatosis phenotype was detected in 23 of 25 (92.0%) C282Y homozygous family members; two family members (8.0%) had hepatic cirrhosis; and four family members (16.0%) had diabetes mellitus attributed to iron overload. However, two C282Y homozygotes (8.0%) had no phenotypic evidence of hemochromatosis and were detected only by HFE genotyping: the 1 1-year-old nephew of one proband and the 32-year-old sister of another proband (Table 3) .
Twenty-three family members were C282YIH63D compound heterozygotes, 8 (34.5%) were siblings of probands, and 3 (7.9%) were spouses or other relatives by marriage ( Table 2 ). Eight of 23 (34.8%) family members who were C282YlH63D compound heterozygotes had a hernochromatosis phenotype (6 men, 2 women). This frequency of hernochromatosis phenotypes was significantly less than that observed among family members who were C282Y homozygotes (34.8% vs. 92.0%, respectively; P < 0.01). Furthermore, no C282YlH63D compound heterozygotes had hepatic cirrhosis or diabetes mellitus, and iron overload was generally less severe in these family members than among those who had a hemochromatosis phenotype associated with C282Y homozyg~sity.'.~-" Fifteen of 23 (65.2%) who were C282YlH63D compound heterozygotes had no phenotypic evidence of hernochromatosis (8 men, 7 women). Among 12 family members who were H63D homozygotes, none had a hemochrornatosis phenotype. Sixty family members were heterozygous for C282Y or H63D mutations; six (10.0%) had a hemochromatosis phenotype (4 men, 2 women), but none had hepatic cirrhosis or diabetes mellitus attributed to iron overload (Tables 2 and 3 ). Thirty family members had no detectable HFE mutant alleles, and none had iron overload. However, the 48-year-old female monozygotic twin of a proband had only persistently elevated values of transferrin saturation (her twin sister had elevated transferrin saturation and iron overload). Taken together, only 4 of 102 (3.9%) family members who had H63D/H63D, C282Ylwt, or H63DIwt genotypes had iron overload (Table 3) .
HFE genotypes and pseudodominant patterns of hemochromatosis inheritance
We observed persons in successive generations who inherited two HFE mutations in 12 kinships; in eleven of these, we also identified a hernochromatosis phenotype in persons of successive generations. We tested the spouses of 20 probands. Eight spouses (40.0%) had one or more mutant HFE alleles; this percentage is similar to the frequency of persons in the general Caucasian population in our geographic area who have one or more HFE mutations (54 of 143; 37.8%). sponding kinships, we also tested one or more offspring. In each of the five kinships, we identified offspring who inherited two mutant HFE alleles and also had a hemochromatosis phenotype. Among the kinships, we identified five additional spouse pairs who had untested offspring at risk to have C282Y homozygosity; four spouse pairs had untested offspring at risk to have C282YlH63D compound heterozygosity. Different HFE genotypes within the same kinship, usually C282Y homozygosity and C282YlH63D compound heterozygosity, were associated with a hemochromatosis phenotype in two or more persons in each of seven kinships. Pedigrees of our families revealed several combinations of HFE genotypes in successive generations that were associated with hemochromatosis phenotypes; two pedigrees are depicted in Figures 1 and 2 .
DISCUSSION
Our results confirm that hemochromatosis phenotypes and abnormal HFE genotypes are common among family members of probands, especially first-degree
The frequency of hemochromatosis phenotypes among our C282Y homozygous family members was particularly high, consistent with previous observations in other C282Y h o r n o~y g o t e s .~~~-l~ HFE genotyping identified two C282Y homozygotes (a prepubertal boy and a premenopausal woman) who did not have a hemochromatosis phenotype. This is in accordance with observations that the frequency of clinical expression of hemochromatosis is lower in children and premenopausal women than in men who are middle-age or older.ls2 The C282YlH63D genotype is associated with a relatively low frequency of clinical expression of hemochromatosis,5~9-1' and iron overload in persons with this genotype is usually of mild or moderate severity.3-5,9-1 I oU r observations in family members of probands corroborate these reports. Whether our family members without a hemochromatosis phenotype, especially those who are C282Y homozygotes or C282YlH63D compound heterozygotes, will eventually develop clinical evidence of hemochromatosis cannot be determined by our study. However, we recommend that persons with these genotypes undergo measurement of serum iron parameters every 1 to 2 years. If serum ferritin concentrations or other clinical parameters indicate that (even mild) iron overload has developed, treatment with phlebotomy and other measures should be initiated.'
Most persons with a hemochromatosis phenotype inherit two mutant HFE allele^.^-^.^-'^ Accordingly, HFE mutation analysis of family members of hemochromatosis probands can reveal various genotypes and their associated risks for the development of phenotypic evidence of hernochromatosis. Detecting C282Y homozygosity (or C282YlH63D compound heterozygosity) in children and young adults who are relatives of probands and applying estimates of penetrance of these g e n o t y p e~~-~.~-I~ can help predict their future likelihood of developing phenotypic evidence of hemochromatosis that will require phlebotomy therapy to prevent iron overload. Furthermore, our observations using HFE mutation analysis confirm and extend the ability to predict the development of a hemochromatosis phenotype in first-degree relatives of probands based on human leukocyte antigen (HLA) typing.I3 HFE genotyping of probands and family members, especially spouses, also makes it possible to assess risk for the inheritance of HFE alleles in untested relatives or in future offspring.14 HFE genotyping could lead to periodic monitoring of serum iron parameters in clinically normal family members some of whom may never develop iron overload or other evidence of hemochromatosis. Contrariwise, probands (and family members) who have one or no detectable HFE mutations can have a hemochromatosis phenotype.15 Taken together, only 5.9% and 3.9% of family members who had the HFE genotypes H63D/H63D, H63D/wt, C282Y/wt, or wtlwt had elevated transferrin saturation values and iron overload, respectively. This is consistent with other studies in which persons with iron overload were unlikely to have these HFE g e n o t y p e~.~-~,~-'~ Although these frequencies (5.9% and 3.9%) are approximately 10-fold greater than the prevalence of hemochromatosis in the general Caucasian pop~lation,'.~ our data suggest that phenotypic tests of iron metabolism are more specific for hemochromatosis in persons with these HFE genotypes (and other family members predicted to have the same HFE genotypes). Because hemochromatosis is common, involves multiple recessive mutations, and has a variable phenotype, phenotyping and genotyping are complementary in screening for hemochromatosis among family members of probands. Furthermore, HFE mutations other than C282Y and H63D have been identified recently,16J7 and it seems likely that these and additional future discoveries will explain why hemochromatosis phenotypes sometimes appear among persons who are heterozygous (or negative) for C282Y or H63D.
